On June 17, Moderna rose 5.09% in regular trading, trading at $58.19/share, with turnover of $119 million. The rally came amid positive momentum following the announcement that its cancer prevention mRNA vaccine mRNA-4194 received clinical trial authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Moderna, in collaboration with Oxford University, developed mRNA-4194 as a preventive vaccine targeting cancers associated with Lynch Syndrome, one of the most common hereditary cancer predispositions with a population incidence of approximately 1 in 300. Patients carry germline mutations in DNA mismatch repair genes including MLH1, MSH2, MSH6, PMS2, and EPCAM, leading to significantly elevated risks of colorectal, endometrial, ovarian, gastric, and pancreatic cancers. The vaccine is designed to provide cross-cancer-type protection via intramuscular injection, leveraging Moderna's established mRNA-LNP platform. Oxford University's Oncology Clinical Trials Office will lead the clinical research, with support from Cancer Research UK.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)